As discussed above, the HGF/SF model may not be appropriate for testing of inhibitors of mutant BRAF, the constitutive MET activity and consequent downstream activation of BRAF in HGF/SF melanomas likely precludes the genesis of BRAF-activating mutations. The gene discussed is MET; the disease is melanoma.